Opus Genetics (IRD) Gains from Sales and Divestitures (2018 - 2025)
Opus Genetics (IRD) reported Gains from Sales and Divestitures of $664734.0 for Q4 2025, up 111.59% year-over-year from $314162.0 in Q4 2024, and up 138.38% on a QoQ basis from $278858.0 in Q2 2025.
Opus Genetics (IRD) has 6 years of Gains from Sales and Divestitures data on file, last reported at $664734.0 in Q4 2025.
- Quarterly Gains from Sales and Divestitures rose 111.59% year-over-year to $664734.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $664734.0 (up 111.59% YoY) and the FY2025 annual result came in at $664734.0, up 111.59% from the prior year.
- Gains from Sales and Divestitures improved to $664734.0 in Q4 2025 per IRD's latest filing, from $278858.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $664734.0 in Q4 2025 and bottomed at $33614.0 in Q2 2023.
- The 4-year median for Gains from Sales and Divestitures is $40000.0 (2021), against an average of $144306.3.
- The widest annual swing landed in 2024, when Gains from Sales and Divestitures soared 834.62%; it then surged 111.59% in 2025.
- Tracing IRD's Gains from Sales and Divestitures over 4 years: stood at $40000.0 in 2021, then decreased by 15.96% to $33614.0 in 2023, then soared by 834.62% to $314162.0 in 2024, then soared by 111.59% to $664734.0 in 2025.
- Per Business Quant, the three latest IRD Gains from Sales and Divestitures figures stand at $664734.0 (Q4 2025), $278858.0 (Q2 2025), and $102676.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 664,734.00 |
| Dec 31, 2025 | 664,734.00 |
| Jun 30, 2025 | 278,858.00 |
| Jun 30, 2025 | 278,858.00 |
| Mar 31, 2025 | 102,676.00 |
| Mar 31, 2025 | 102,676.00 |
| Dec 31, 2024 | 314,162.00 |
| Dec 31, 2024 | 314,162.00 |
| Sep 30, 2024 | 144,162.00 |
| Sep 30, 2024 | 144,162.00 |
| Jun 30, 2024 | 104,880.00 |
| Jun 30, 2024 | 104,880.00 |
| Mar 31, 2024 | 39,282.00 |
| Mar 31, 2024 | 39,282.00 |
| Dec 31, 2023 | 33,614.00 |
| Dec 31, 2023 | 33,614.00 |
| Jun 30, 2023 | 33,614.00 |
| Jun 30, 2023 | 33,614.00 |
| Dec 31, 2021 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 40,000.00 |
| Mar 31, 2021 | 40,000.00 |
| Mar 31, 2021 | 40,000.00 |
| Dec 31, 2019 | 64,552.00 |
| Dec 31, 2019 | 64,552.00 |
| Sep 30, 2019 | 464.00 |
| Sep 30, 2019 | 464.00 |
| Jun 30, 2019 | 464.00 |
| Jun 30, 2019 | 464.00 |
| Mar 31, 2019 | 464.00 |
| Mar 31, 2019 | 464.00 |
| Dec 31, 2018 | 18,075.00 |
| Dec 31, 2018 | 18,075.00 |
| Sep 30, 2018 | 11,825.00 |
| Sep 30, 2018 | 11,825.00 |
| Jun 30, 2018 | 11,825.00 |
| Jun 30, 2018 | 11,825.00 |
| Mar 31, 2018 | 11,825.00 |
| Mar 31, 2018 | 11,825.00 |